<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00757549</url>
  </required_header>
  <id_info>
    <org_study_id>MC057M</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC057M</secondary_id>
    <secondary_id>08-002166</secondary_id>
    <secondary_id>NCI-2009-01193</secondary_id>
    <nct_id>NCT00757549</nct_id>
  </id_info>
  <brief_title>3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx</brief_title>
  <official_title>Comparison of FLT and FDG PET in the Evaluation of Response to Cetuximab, Cisplatin and Radiation Therapy in Advanced Head and Neck Malignancies or Response to Standard Chemo-radiotherapy in Esophageal Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) and&#xD;
      fludeoxyglucose F 18 (FDG) PET scans, may help doctors predict a patient's response to&#xD;
      treatment and help plan the best treatment.&#xD;
&#xD;
      PURPOSE: This pilot trial is studying FLT and FDG PET scans to see how well they evaluate&#xD;
      response to cetuximab, cisplatin, and radiation therapy in patients with advanced cancer of&#xD;
      the oropharynx, larynx, or hypopharynx.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess whether 3'-deoxy-3'-[18F] fluorothymidine (FLT) and fludeoxyglucose F 18 (FDG)&#xD;
           PET scans can be used to identify patients with advanced squamous cell carcinoma of the&#xD;
           oropharynx, larynx, or hypopharynx who have a biochemical response after 2 weeks of&#xD;
           induction therapy with cetuximab.&#xD;
&#xD;
        -  To assess whether FLT and FDG PET imaging-based response after 20-30 Gy of radiotherapy&#xD;
           is predictive of disease control at 6 months after completion of therapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess whether FLT and FDG PET imaging-based response after cetuximab therapy and/or&#xD;
           20-30 Gy of radiotherapy is predictive of pathologic complete response in these&#xD;
           patients.&#xD;
&#xD;
        -  To assess whether FLT and FDG PET imaging-based response after cetuximab therapy and/or&#xD;
           20-30 Gy of radiotherapy is predictive of disease-free survival at 2 years in these&#xD;
           patients.&#xD;
&#xD;
        -  To correlate suppression of FLT uptake after cetuximab therapy with thymidine kinase 1&#xD;
           activity and/or expression, proliferation, microvessel density, apoptosis, and signaling&#xD;
           pathway analyses.&#xD;
&#xD;
        -  To correlate suppression of FDG uptake after cetuximab therapy with expression of&#xD;
           hexokinases, glucose transporter proliferation, microvessel density, apoptosis, and&#xD;
           signaling pathway analyses.&#xD;
&#xD;
        -  To test and refine the ability of a novel commercial software package to quantify&#xD;
           treatment-induced structural and functional/molecular volumetric and sub-volumetric&#xD;
           change.&#xD;
&#xD;
        -  To develop a working method for expressing change and predicting outcome.&#xD;
&#xD;
      OUTLINE: Patients receive cetuximab IV on days 1 and 8 of course 1. Beginning in course 2 and&#xD;
      all subsequent courses, patients receive cetuximab IV and cisplatin IV over 2 hours on day 1&#xD;
      and undergo radiotherapy once daily 5 days a week for 7 weeks. Treatment repeats every 7 days&#xD;
      for a total of 8 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo 3'-deoxy-3'-[18F] fluorothymidine and fludeoxyglucose F 18 (FDG) PET scans&#xD;
      at baseline, after the second dose of cetuximab, after 20-30 Gy of radiotherapy, and then at&#xD;
      6 weeks and 6 months after completion of radiotherapy.&#xD;
&#xD;
      Patients undergo tumor tissue biopsies at baseline and after the first dose of cetuximab for&#xD;
      correlative laboratory studies. Samples are analyzed for proliferation (Ki-67 labeling&#xD;
      index), microvessel density (CD-31 staining), apoptosis (TUNEL assay and caspase-3 by IHC)&#xD;
      signaling pathway (expression of EGFR, AKT, and MAPK by IHC), molecules affecting FDG uptake&#xD;
      (expression of GLUT1, GLUT3, and hexokinase by IHC), and thymidine kinase 1 activity or&#xD;
      expression.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">October 25, 2017</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in the standard uptake value levels calculated for the identified volumes of interest for FLT and FDG PET scans from baseline to after 2 weeks of cetuximab therapy and from baseline to after 20-30 Gy of radiotherapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantified change values (after cetuximab therapy and after 20-30 Gy of radiotherapy) for the FLT and FDG PET scan-based topographic profiles created using the ImQuant software package</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>TdT-mediated dUTP nick end labeling assay</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>3'-deoxy-3'-[18F]fluorothymidine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed squamous cell carcinoma of the oropharynx,&#xD;
             larynx, or hypopharynx&#xD;
&#xD;
               -  Advanced disease&#xD;
&#xD;
          -  Requires chemoradiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy ≥ 16 weeks&#xD;
&#xD;
          -  Weight loss ≤ 10% within the past 3 months&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST ≤ 3 times ULN&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL&#xD;
&#xD;
          -  Creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No NYHA class III-IV heart disease&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No poorly controlled diabetes that would limit the ability to obtain reliable&#xD;
             fludeoxyglucose F 18 PET scan results&#xD;
&#xD;
          -  No other severe underlying disease that, in the judgment of the investigator, would&#xD;
             preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 2 weeks since prior major surgery and recovered&#xD;
&#xD;
          -  No prior radiotherapy to the planned treatment field&#xD;
&#xD;
          -  No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jann N. Sarkaria, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>September 22, 2008</study_first_submitted>
  <study_first_submitted_qc>September 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2008</study_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

